Cargando…
Low interferon-gamma release in response to phytohemagglutinin predicts the high severity of diseases
A clinically useful immune biomarker could potentially assist clinicians in their decision making. We stimulated T-cell proliferation to secret interferon gamma (IFN-γ) by phytohemagglutinin, and then measured the production of IFN-γ (mitogen value [M value]). We aimed to determine the relationship...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709005/ https://www.ncbi.nlm.nih.gov/pubmed/31145331 http://dx.doi.org/10.1097/MD.0000000000015843 |
_version_ | 1783446108522938368 |
---|---|
author | He, Xing Liu, Li-Ying Ji, Xiao-Kun Xian, Ya-Bin Yan, Yong-Jun Xu, Hui-Juan Sha, Li Pu, Chun-Li Zhou, Jun-Yan Yuan, Chun-Yan Yang, Mei Zheng, Song-Guo |
author_facet | He, Xing Liu, Li-Ying Ji, Xiao-Kun Xian, Ya-Bin Yan, Yong-Jun Xu, Hui-Juan Sha, Li Pu, Chun-Li Zhou, Jun-Yan Yuan, Chun-Yan Yang, Mei Zheng, Song-Guo |
author_sort | He, Xing |
collection | PubMed |
description | A clinically useful immune biomarker could potentially assist clinicians in their decision making. We stimulated T-cell proliferation to secret interferon gamma (IFN-γ) by phytohemagglutinin, and then measured the production of IFN-γ (mitogen value [M value]). We aimed to determine the relationship between the M value, clinical severity, and outcomes of diseases. In all, 484 patients admitted to intensive care units were enrolled in this retrospective study. The Acute Physiology and Chronic Health Evaluation II (APACHE II) scores were collected within the first 24 hours. M value, C-reaction protein (CRP), procalcitonin (PCT), erythrocyte sedimentation rate (ESR), and routine blood tests were analyzed and collected during the study. When APACHE II scores were greater than 15 and M values were less than 6, the hospital mortality rose in a straight line. There was an inverse correlation between APACHE II score and M value (r(s) = −0.212, P < .001). There was a positive correlation between M value and lymphocyte numbers (b’ = 0.249, P < .001); however, there was an inverse correlation between M value and WBC (b’ = −0.230, P < .001), and ESR (b’ = −0.100, P = .029). Neurological diseases had the greatest influence on APACHE II scores (b’ = 10.356, P < .001), whereas respiratory diseases had the greatest influence on M value (b’ = 1.933, P < .001). Furthermore, in the respiratory system, severe pneumonia had a greater influence on M value. Taking the APACHE II score as the gold standard, the area under the curve of M was 0.632 (95% confidence interval [CI] 0.575–0.690, P < .001), PCT was 0.647 (95% CI 0.589–0.705, P < .001), CRP was 0.570 (95% CI 0.511–0.629, P = .022), and ESR was 0.553 (95% CI 0.494–0.612, P = .078). Divided by M value = 5, the positive predictive value of the M value is 37.22% (115/309) and negative predictive value is 75.43% (132/175). The results show that the M values, PCT, and CRP were better than ESR to predict the severity of diseases. The number and proportion of lymphocytes also affected the result of the M value. To a certain extent, the M value may be a clinically useful immune biomarker, which may help clinicians objectively evaluate the severity of diseases, especially in the respiratory system. |
format | Online Article Text |
id | pubmed-6709005 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-67090052019-10-01 Low interferon-gamma release in response to phytohemagglutinin predicts the high severity of diseases He, Xing Liu, Li-Ying Ji, Xiao-Kun Xian, Ya-Bin Yan, Yong-Jun Xu, Hui-Juan Sha, Li Pu, Chun-Li Zhou, Jun-Yan Yuan, Chun-Yan Yang, Mei Zheng, Song-Guo Medicine (Baltimore) Research Article A clinically useful immune biomarker could potentially assist clinicians in their decision making. We stimulated T-cell proliferation to secret interferon gamma (IFN-γ) by phytohemagglutinin, and then measured the production of IFN-γ (mitogen value [M value]). We aimed to determine the relationship between the M value, clinical severity, and outcomes of diseases. In all, 484 patients admitted to intensive care units were enrolled in this retrospective study. The Acute Physiology and Chronic Health Evaluation II (APACHE II) scores were collected within the first 24 hours. M value, C-reaction protein (CRP), procalcitonin (PCT), erythrocyte sedimentation rate (ESR), and routine blood tests were analyzed and collected during the study. When APACHE II scores were greater than 15 and M values were less than 6, the hospital mortality rose in a straight line. There was an inverse correlation between APACHE II score and M value (r(s) = −0.212, P < .001). There was a positive correlation between M value and lymphocyte numbers (b’ = 0.249, P < .001); however, there was an inverse correlation between M value and WBC (b’ = −0.230, P < .001), and ESR (b’ = −0.100, P = .029). Neurological diseases had the greatest influence on APACHE II scores (b’ = 10.356, P < .001), whereas respiratory diseases had the greatest influence on M value (b’ = 1.933, P < .001). Furthermore, in the respiratory system, severe pneumonia had a greater influence on M value. Taking the APACHE II score as the gold standard, the area under the curve of M was 0.632 (95% confidence interval [CI] 0.575–0.690, P < .001), PCT was 0.647 (95% CI 0.589–0.705, P < .001), CRP was 0.570 (95% CI 0.511–0.629, P = .022), and ESR was 0.553 (95% CI 0.494–0.612, P = .078). Divided by M value = 5, the positive predictive value of the M value is 37.22% (115/309) and negative predictive value is 75.43% (132/175). The results show that the M values, PCT, and CRP were better than ESR to predict the severity of diseases. The number and proportion of lymphocytes also affected the result of the M value. To a certain extent, the M value may be a clinically useful immune biomarker, which may help clinicians objectively evaluate the severity of diseases, especially in the respiratory system. Wolters Kluwer Health 2019-05-31 /pmc/articles/PMC6709005/ /pubmed/31145331 http://dx.doi.org/10.1097/MD.0000000000015843 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 |
spellingShingle | Research Article He, Xing Liu, Li-Ying Ji, Xiao-Kun Xian, Ya-Bin Yan, Yong-Jun Xu, Hui-Juan Sha, Li Pu, Chun-Li Zhou, Jun-Yan Yuan, Chun-Yan Yang, Mei Zheng, Song-Guo Low interferon-gamma release in response to phytohemagglutinin predicts the high severity of diseases |
title | Low interferon-gamma release in response to phytohemagglutinin predicts the high severity of diseases |
title_full | Low interferon-gamma release in response to phytohemagglutinin predicts the high severity of diseases |
title_fullStr | Low interferon-gamma release in response to phytohemagglutinin predicts the high severity of diseases |
title_full_unstemmed | Low interferon-gamma release in response to phytohemagglutinin predicts the high severity of diseases |
title_short | Low interferon-gamma release in response to phytohemagglutinin predicts the high severity of diseases |
title_sort | low interferon-gamma release in response to phytohemagglutinin predicts the high severity of diseases |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709005/ https://www.ncbi.nlm.nih.gov/pubmed/31145331 http://dx.doi.org/10.1097/MD.0000000000015843 |
work_keys_str_mv | AT hexing lowinterferongammareleaseinresponsetophytohemagglutininpredictsthehighseverityofdiseases AT liuliying lowinterferongammareleaseinresponsetophytohemagglutininpredictsthehighseverityofdiseases AT jixiaokun lowinterferongammareleaseinresponsetophytohemagglutininpredictsthehighseverityofdiseases AT xianyabin lowinterferongammareleaseinresponsetophytohemagglutininpredictsthehighseverityofdiseases AT yanyongjun lowinterferongammareleaseinresponsetophytohemagglutininpredictsthehighseverityofdiseases AT xuhuijuan lowinterferongammareleaseinresponsetophytohemagglutininpredictsthehighseverityofdiseases AT shali lowinterferongammareleaseinresponsetophytohemagglutininpredictsthehighseverityofdiseases AT puchunli lowinterferongammareleaseinresponsetophytohemagglutininpredictsthehighseverityofdiseases AT zhoujunyan lowinterferongammareleaseinresponsetophytohemagglutininpredictsthehighseverityofdiseases AT yuanchunyan lowinterferongammareleaseinresponsetophytohemagglutininpredictsthehighseverityofdiseases AT yangmei lowinterferongammareleaseinresponsetophytohemagglutininpredictsthehighseverityofdiseases AT zhengsongguo lowinterferongammareleaseinresponsetophytohemagglutininpredictsthehighseverityofdiseases |